G. E. Blouse

发表

Biochemical properties of plasminogen activator inhibitor-1.

P. Andreasen, D. Dupont, J. B. Madsen, 2009, Frontiers in bioscience.

A Peptide Accelerating the Conversion of Plasminogen Activator Inhibitor-1 to an Inactive Latent State

A. Gils, P. Declerck, P. Andreasen, 2008, Molecular Pharmacology.

A Deletion Mutant of Vitronectin Lacking the Somatomedin B Domain Exhibits Residual Plasminogen Activator Inhibitor-1-binding Activity*

G. E. Blouse, C. Peterson, K. Minor, 2008, Journal of Biological Chemistry.

Releasing the brakes in coagulation Factor IXa by co-operative maturation of the substrate-binding site.

O. Olsen, H. Brandstetter, G. E. Blouse, 2016, The Biochemical journal.

A Mechanism for Assembly of Complexes of Vitronectin and Plasminogen Activator Inhibitor-1 from Sedimentation Velocity Analysis*

D. Lawrence, P. Schuck, G. E. Blouse, 2005, Journal of Biological Chemistry.

Factor VIII with a 237 amino acid B‐domain has an extended half‐life in F8‐knockout mice

L. Thim, H. Rahbek-Nielsen, M. Loftager, 2019, Journal of thrombosis and haemostasis : JTH.

Characterization of ATP and P2 agonists binding to the cardiac plasma membrane P1,P4-diadenosine 5'-tetraphosphate receptor.

G. E. Blouse, R. H. Hilderman, G. Liu, 1998, Biochimica et biophysica acta.

19F NMR studies of plasminogen activator inhibitor-1.

A. Szabo, L. Luck, G. E. Blouse, 2004, Biochemistry.

Evidence for a Pre-latent Form of the Serpin Plasminogen Activator Inhibitor-1 with a Detached β-Strand 1C*

A. Gils, P. Declerck, P. Andreasen, 2006, Journal of Biological Chemistry.

A Novel Mode of Intervention with Serine Protease Activity

K. Mortensen, P. Andreasen, J. Quigley, 2009, Journal of Biological Chemistry.

A Urokinase-type Plasminogen Activator-inhibiting Cyclic Peptide with an Unusual P2 Residue and an Extended Protease Binding Surface Demonstrates New Modalities for Enzyme Inhibition*

P. Andreasen, G. E. Blouse, T. Wind, 2005, Journal of Biological Chemistry.

Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.

S. Sheng, Xiaohua Li, J. Anagli, 2006, Cancer research.

Characterization of a Site on PAI-1 That Binds to Vitronectin Outside of the Somatomedin B Domain*

P. Andreasen, G. E. Blouse, J. Jensen, 2008, Journal of Biological Chemistry.

Structural Determinants of the Calpain Inhibitory Activity of Calpastatin Peptide B27-WT*

J. Anagli, S. Weinsheimer, G. E. Blouse, 2003, The Journal of Biological Chemistry.

The Contribution of the Exosite Residues of Plasminogen Activator Inhibitor-1 to Proteinase Inhibition*

C. Ibarra, G. E. Blouse, J. Shore, 2004, Journal of Biological Chemistry.

Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements.

J. Anagli, M. Ploug, H. Gårdsvoll, 2009, Biochemistry.

Enthalpy measurement using calorimetry shows a significant difference in potential energy between the active and latent conformations of PAI-1

Westley A. Sherman, T. Tran, G. E. Blouse, 2005, Biological chemistry.

Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

K. Mortensen, Mingdong Huang, Zhuo Chen, 2011, The Biochemical journal.

Nonproteolytic induction of catalytic activity into the single-chain form of urokinase-type plasminogen activator by dipeptides.

P. Andreasen, G. E. Blouse, A. Christensen, 2009, Biochemistry.

Mutation of the highly conserved tryptophan in the serpin breach region alters the inhibitory mechanism of plasminogen activator inhibitor-1.

L. Lutter, G. E. Blouse, J. Shore, 2003, Biochemistry.

Distortion of the Catalytic Domain of Tissue-type Plasminogen Activator by Plasminogen Activator Inhibitor-1 Coincides with the Formation of Stable Serpin-Proteinase Complexes*

G. E. Blouse, J. Shore, M. Perron, 2003, Journal of Biological Chemistry.

A Deletion Mutant of Vitronectin Lacking the Somatomedin B Domain Exhibits Residual Plasminogen Activator Inhibitor-1-binding Activity*

G. E. Blouse, C. Peterson, K. Minor, 2008, Journal of Biological Chemistry.

Pegylated CB2782: a Complement Factor C3-Inactivating Protease and Potential Long-Acting Treatment for Dry AMD

E. Furfine, M. Stanton, G. E. Blouse, 2019 .

Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy

Rob C. van Wijk, G. E. Blouse, U. Simonsson, 2023, CPT: pharmacometrics & systems pharmacology.

Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients

G. E. Blouse, U. Simonsson, E. Gorina, 2023, Advances in therapy.

The Contribution of the Exosite Residues of Plasminogen Activator Inhibitor-1 to Proteinase Inhibition*

C. Ibarra, G. E. Blouse, J. Shore, 2004, Journal of Biological Chemistry.

Characterization of a Site on PAI-1 That Binds to Vitronectin Outside of the Somatomedin B Domain*

P. Andreasen, G. E. Blouse, J. Jensen, 2008, Journal of Biological Chemistry.

Structural Determinants of the Calpain Inhibitory Activity of Calpastatin Peptide B27-WT*

J. Anagli, S. Weinsheimer, G. E. Blouse, 2003, The Journal of Biological Chemistry.

Polypeptides de facteur ix modifiés et leurs applications

G. E. Blouse, Christopher D. Thanos, Edwin L. Madison, 2011 .

Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors

J. Nyberg, G. E. Blouse, U. Simonsson, 2024, Clinical pharmacology and therapeutics.

Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug

G. E. Blouse, U. Simonsson, S. Desai, 2022, CPT: pharmacometrics & systems pharmacology.